^
    Back
    Association details:
    Biomarker:PTEN deletion
    Cancer:Endometrial Cancer
    Drug:Lynparza (olaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Nat Rev Clin Oncol
    Title:

    Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer

    Excerpt:
    After 8 months of olaparib treatment the patient developed objective disease progression. The tumor biopsy was negative for somatic BRCA1 and BRCA2 mutations, but displayed loss of PTEN, which has been suggested to be another predictive marker for sensitivity to PARP inhibitors.
    DOI:
    10.1038/nrclinonc.2011.42